1-7 of 7
Yosef Landesman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M.E. Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, Leah Henegar, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Morten Mau-Sørensen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 452–460.
https://doi.org/10.1158/1078-0432.CCR-21-2225
Published: 01 February 2022
View article titled, A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Open the PDF for A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study

Erlene K. Seymour, Husain Yar Khan, Yiwei Li, Mahmoud Chaker, Irfana Muqbil, Amro Aboukameel, Radhakrishanan Ramchandren, Christiane Houde, Golbon Sterbis, Jay Yang, Divaya Bhutani, Silvana Pregja, Kathy Reichel, Amy Huddlestun, Colleen Neveux, Kelly Corona, Yosef Landesman, Jatin Shah, Michael Kauffman, Sharon Shacham, Ramzi M. Mohammad, Asfar S. Azmi, Jeffrey A. Zonder
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3307–3316.
https://doi.org/10.1158/1078-0432.CCR-20-4929
Published: 15 June 2021
View article titled, Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
Open the PDF for Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs

Julia Etchin, Alla Berezovskaya, Amy S. Conway, Ilene A. Galinsky, Richard M. Stone, Erkan Baloglu, William Senapedis, Yosef Landesman, Michael Kauffman, Sharon Shacham, Jean CY Wang, A Thomas Look
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 39.
https://doi.org/10.1158/1557-3265.HEMMAL17-39
Published: 14 December 2017
View article titled, Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs
Journal Articles

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

Thomas Vercruysse, Jolien De Bie, Jasper E. Neggers, Maarten Jacquemyn, Els Vanstreels, Jonathan L. Schmid-Burgk, Veit Hornung, Erkan Baloglu, Yosef Landesman, William Senapedis, Sharon Shacham, Antonis Dagklis, Jan Cools, Dirk Daelemans
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2528–2541.
https://doi.org/10.1158/1078-0432.CCR-16-1580
Published: 14 May 2017
View article titled, The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
Open the PDF for The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia in another window
Includes: Multimedia, Supplementary data
Journal Articles

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1552–1563.
https://doi.org/10.1158/1078-0432.CCR-16-1333
Published: 14 March 2017
View article titled, Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Open the PDF for Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, Xiaomei Meng, Tzung-Huei Lai, Betina McNeil, Bhavana Bhatnagar, Sharon Shacham, Michael Kauffman, Adrienne M. Dorrance, William Blum, Deepa Sampath, Yosef Landesman, Ramiro Garzon
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6142–6152.
https://doi.org/10.1158/1078-0432.CCR-15-2885
Published: 15 December 2016
View article titled, XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Open the PDF for XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus in another window
Includes: Supplementary data
Journal Articles

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer

Isabel Ferreiro-Neira, Nancy E. Torres, Lukas F. Liesenfeld, Carlos H.F. Chan, Tristan Penson, Yosef Landesman, William Senapedis, Sharon Shacham, Theodore S. Hong, James C. Cusack
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1663–1673.
https://doi.org/10.1158/1078-0432.CCR-15-0978
Published: 31 March 2016
View article titled, XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer
Open the PDF for XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer in another window
Includes: Supplementary data